The market demand for hydroxychloroquine in China is relatively large. There are two companies approved for manufacturing hydroxychloroquine, namely Shanghai Zhongxi Pharmaceutical Co., Ltd. and Sanofi-aventis Ireland Ltd. Shanghai Zhongxi Pharmaceutical Co., Ltd. has a larger sales market share with lower prices advantage. In 2020, the sales amount of Shanghai Zhongxi Pharmaceutical is as high as CNY 233 million, and the market share is 68.05%.
Hydroxychloroquine has been tried out in search of its effectiveness of prevention and treatment for coronavirus diseases in the first half of 2020. In March 2020, the Shanghai Municipal Health Commission in China recommended that hydroxychloroquine be used to treat mild to moderate new coronavirus diseases. The preliminary results of clinical studies in China and France showed that hydroxychloroquine is effective and safe. On March 28, 2020, the U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for use of Hydroxychloroquine Sulfate for the treatment of 2019 Coronavirus disease. However, on July 4, 2020, the World Health Organization announced that it would stop the hydroxychloroquine trial on the grounds because “the mortality rate of hospitalized patients with the coronary disease could not be relieved during the trial”. In August 2020, the "Covid-19 Diagnosis and Treatment Plan (Trial Eighth Edition)" issued by the National Health Commission of China stated that "hydroxychloroquine or combined use with azithromycin is not recommended."
The sales volume increased in the short term when used in the experimental prevention and treatment at the beginning of 2020. It is predicted that its sales will gradually return to the original level, that is, it is mainly used for the treatment of malaria and rheumatoid arthritis.
Topics Covered:
- The impact of COVID-19 on China's hydroxychloroquine market
- Market size of hydroxychloroquine in China
- Major hydroxychloroquine manufacturers in China
- Prices of hydroxychloroquine in China
- Major factors affecting the development of China's hydroxychloroquine market
- Prospect of China's hydroxychloroquine market
Table of Contents
Samples
LOADING...
Companies Mentioned
- Shanghai Zhongxi Pharmaceutical
- Sanofi-aventis Ireland
Methodology
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 50 |
| Published | April 2021 |
| Forecast Period | 2016 - 2025 |
| Estimated Market Value ( CNY | CNY 258 Million |
| Forecasted Market Value ( CNY | CNY 503 Million |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | China |
| No. of Companies Mentioned | 2 |
